This Is MS Multiple Sclerosis Knowledge & Support Community

1) TYSABRI® Demonstrates Improvement in Cognitive Function
2) TYSABRI® Demonstrate Significant Reduction in Steroid Use and Hospitalizations
3) TYSABRI® Has Sustained Effect on Relapse Rate for up to Three Years

And an "older" data release re: TYSABRI® Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis - 6 April 2006

To view the full articles, go to: www.mspatientsforchoice.org/

Lauren

Looks like Biogen's marketing and sales department is very busy these days making sure that Tysabri gets its market share.

Interesting to note that Teva, the makers of Copaxone, has been releasing newly analyzed data showing that Copaxone is providing MS patients greater than ever benefits.

The marketing battles among the big four MS pharmas is in full swing!

Harry

But none of them even come close to Tysabri's data, care to share the link for your Teva/Copaxone data so all of us can compare it to Tysabri's?

Personally, I have more faith in the Tovaxin treatment then the Tysabri but that's just me. My neuro said the current research for Tovaxin seems very promising. More promising than anything else in clinical trials right now including Tysabri. However for those of you getting Tysabri I wish you the best and I hope it really does work as well as it claims.

msladyinca wrote:But none of them even come close to Tysabri's data, care to share the link for your Teva/Copaxone data so all of us can compare it to Tysabri's?

Here are two links...

http://www.thisisms.com/ftopict-3029.html

http://www.infozine.com/news/stories...iew/sid/18283/

I'm not a "fan" of the CRABs either but have noticed in the past month or so that Teva with Copaxone and Biogen with Tysabri have been making a number of press releases to market their respective MS drugs. These two companies appear to be in a head-to-head marketing/sales battle to try and improve their market share and a few percent increase in this area translates into millions of dollars of additional revenue. It is especially critical for Biogen/Elan because recent comments in the financial world have stated that Tysabri sales aren't going to be anywhere near the original expectation of income. This creates an additional problem for Biogen since they only get 50% of Tysabri's income and if Tysabri effects Avonex's sales in a negative way, the problem becomes worse.

Neither side can compare their product to each other because there certainly hasn't been any kind of trial doing this...at least not yet! Biogen gave Avonex to Tysabri users in the trials to see if the two would give a better result than Tysabri or Avonex alone but we all know what happened in that situation.

It's going to be a big marketing battle for sure between Biogen and Teva because the amount of money at issue here is huge!

Harry

The study cohort consisted of 96 women and 12 men

So that's 108 Copaxone trial patients in the Czech Republic as opposed to 3,000 Tysabri US patients...with no data showing Improvement in QoL, no data for Significant Reduction in Steroid Use and Hospitalizations, and no data showing Cognitive Function Improvement...hardly seems worth the time to even mention Copaxone, but hey, that's just me.

It is especially critical for Biogen/Elan because recent comments in the financial world have stated that Tysabri sales aren't going to be anywhere near the original expectation of income.

Financial ANALysists aren't going to drive Tysabri uptake and demand, patients will.

Thanks for the first link, the second link revealed nothing as it didn't work, but thanks anyway Harry.

And thank you SO much Merlin, best wishes to you too for Tovaxin!

Have a good weekend guys,

Lauren

So that's 108 Copaxone trial patients in the Czech Republic as opposed to 3,000 Tysabri US patients...with no data showing Improvement in QoL, no data for Significant Reduction in Steroid Use and Hospitalizations, and no data showing Cognitive Function Improvement...hardly seems worth the time to even mention Copaxone, but hey, that's just me.

I believe you are missing the point I'm trying to make here. I agree that the data Teva is posting is being "dredged" to make it sound like Copaxone is so good. But what Teva is doing is slick marketing in order to generate a rise in their stock value. Now if MS patients and their docs happen to read this information and decide to use Copaxone, that ensures more market share. Biogen does exactly the same thing as does Serono with Rebif. This line of action has little to do with how good the drugs may or may not be but is a marketing war.

Financial ANALysists aren't going to drive Tysabri uptake and demand, patients will.

You are absolutely right....the main purpose of these financial press releases is to get the business investors to purchase the company's stock because that's how you quickly raise the worth of your company. The secondary goal is to try and influence MS patients and their docs.

Thanks for the first link, the second link revealed nothing as it didn't work, but thanks anyway Harry.

Hmmm...worked this morning when I tested it...let's try again.

http://www.infozine.com/news/stories/op ... sid/18283/

I tried it again before submitting the message and it did work.

Harry

i've been reading all the Ty forums and excuse my french but wtf. yes no, good bad, forsure maybe, how do you make a decision with this shit....

Robbie,

robbie wrote:i've been reading all the Ty forums and excuse my french but wtf. yes no, good bad, forsure maybe, how do you make a decision with this shit....

I can certainly understand your frustration with all of this. Even the expert docs have differences of opinion when it comes to the MS drugs and especially with Tysabri. The best way to make a decision is to read as much info as you can about the drug, sit down with your doc and discuss the options. Ensure that you have written down any questions you may have before you go to his/her office because guaranteed you won't remember everything you want to ask him/her. Then take some time after the discussion and decide what you want to do.

Harry